Arquivos do dia: Novembro 17, 2021
Diretriz ESC para o diagnóstico e tratamento de doença cardiovascular durante a pandemia de COVID-19.
17 Nov, 2021 | 13:12hESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic – European Heart Journal
Part 1—epidemiology, pathophysiology, and diagnosis
Part 2—care pathways, treatment, and follow-up
Comunicado de imprensa: European Society of Cardiology COVID-19 guidance launched – European Society of Cardiology
Comentários no Twitter
New: @escardio guidance for the diagnosis and management of #CardiovascularDisease during the #COVID19 pandemic: Part 1 – Epidemiology, pathophysiology and diagnosis https://t.co/8yGWQ5qgPT#cardiotwitter #cardiology #ESCYoung #ESCSoT #heartteam #cvnurses #alliedprofessionals pic.twitter.com/5YM4DDjzGW
— European Society of Cardiology (@escardio) November 16, 2021
NEW: @escardio guidance for the diagnosis and management of #CardiovascularDisease during the #COVID19 pandemic: part 2—care pathways, treatment, and follow-up https://t.co/6DkVWWjZY6#cardiotwitter #ESCYoung #ESCSoT #heartteam #cvnurses #alliedprofessionals #cardiology pic.twitter.com/yC6PD8a1hS
— European Society of Cardiology (@escardio) November 16, 2021
Estudo observacional mostra que o monitoramento de pacientes com Covid-19 via mensagens de texto, propiciando que eles relatassem a piora dos sintomas, foi associado a desfechos melhores.
17 Nov, 2021 | 13:10hComunicado de imprensa: Automated Texting System Saved Lives Weekly During First COVID Surge – Penn Medicine
Comentários:
Monitoring outpatients by text appeared to reduce mortality from COVID-19 – ACP Internist
Texting saved lives during Covid. What does that mean for health care’s future? – STAT
Comentário do autor no Twitter (fio – clique para saber mais)
1/ For the >80,000 people in the U.S who will test positive for #Covid19 today, what can we offer to support access to care but help them safely remain at home?
Our team is excited to finally share important, new findings out today in @AnnalsofIM
👉https://t.co/VOtpucwWGD pic.twitter.com/UbNRP5bnW4— M. Kit Delgado, MD, MS (@kit_delgadoMD) November 16, 2021
Estudo de caso-controle | Distúrbios do sono estão associados a desfechos mais graves de COVID-19.
17 Nov, 2021 | 13:08hComunicado de imprensa: Sleep disorders linked with more severe outcomes from COVID-19, study suggests – Cleveland Clinic
Estudo original: Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System – JAMA Network Open
Comentário: Some sleep disorders may lead to worse COVID-19 outcomes – CIDRAP
Comentário no Twitter
This case-control study found that among patients infected with #SARSCoV2, sleep-related hypoxia was an associated risk factor for detrimental #COVID19 outcomes. https://t.co/oWjPxBSxT8
— JAMA Network Open (@JAMANetworkOpen) November 10, 2021
Grandes questões sobre as doses de reforço das vacinas contra Covid-19 – “Desde o porquê até para quem, ainda precisamos de muitas respostas sobre as doses de reforço.”
17 Nov, 2021 | 13:06hThe big questions about Covid-19 booster shots – Vox
Comentário no Twitter
1/ Thoughtful piece by @voxdotcom's @germanrlopez on COVID vaccine boosters.
In good company with @ashishkjha @DrPaulOffit @MonicaGandhi9 @jenkatesdc.https://t.co/pOwZLkmJHn pic.twitter.com/ZAD7AOj0Vz
— Céline Gounder, MD, ScM, FIDSA (@celinegounder) November 12, 2021
Atendimento dos sintomas pós-COVID: um guia para médicos da atenção primária.
17 Nov, 2021 | 13:05hConteúdos relacionados:
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)
Pílula da Pfizer contra COVID deve ser fabricada e vendida mais barata em 95 países pobres.
17 Nov, 2021 | 13:03hPfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries – HealthDay
Ver também:
Pfizer agrees to license generic versions of its COVID-19 pill — in some countries – NPR
Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries – The New York Times (poucos artigos gratuitos por mês)
MSF responde à licença da Pfizer e do Medicines Patent Pool para o novo tratamento da Covid-19 – “O acordo, porém, cobre somente 53% da população mundial e exclui pessoas em diversos países de média renda, deixando esse medicamento promissor fora do alcance de milhões de pessoas.”
17 Nov, 2021 | 13:01h
Comentário no Twitter
Pfizer's deal w/ the Medicines Patent Pool for its COVID-19 treatment doesn't allow enough generic production & leaves this medicine out of reach for millions.
This is yet another restrictive voluntary license as cases continue to rise in many countries. https://t.co/WbVmUt9nrH
— Doctors w/o Borders (@MSF_USA) November 16, 2021
Diretriz | Cuidado pré-operatório na cirurgia de catarata – “Apesar das evidências questionando a utilidade de testes antes da cirurgia de catarata, estudos sugerem que exames e consultas médicas antes desse tipo de cirurgia continuam aumentando.”
17 Nov, 2021 | 12:59h
Comentário no Twitter
Nicely written position paper on preop care for cataract surgery. Addresses the most frequent questions (although actual study data is limited). Basically no tests, continue meds, and proceed in most cases unless recent MI,PCI,VTE,CVA,DKA, or HTN urgency. https://t.co/PLHm1LjhZg
— Steven Cohn, MD (@preopconsult) November 16, 2021
Diretriz AAN | Terapia dopaminérgica para sintomas motores na doença de Parkinson precoce.
17 Nov, 2021 | 12:57hComunicado de imprensa: AAN Issues Guideline for Treatment of Early Parkinson’s Disease – American Academy of Neurology
Metanálise de dados de participantes individuais nos principais estudos randomizados mostrou que o tratamento da hipertensão com inibidores da enzima conversora de angiotensina (IECA) ou bloqueadores do receptor de angiotensina (BRA) reduziu o risco de diabetes tipo 2 em comparação a outros medicamentos.
17 Nov, 2021 | 12:55hComentários:
Blood pressure drugs could prevent type 2 diabetes, study finds – The Guardian